Search the Community
Showing results for tags 'belimumab'.
Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus. We show that Belimumab-mediated B-cell activating factor depletion reduces the Transitional 2 subset in patients. PubMed, Lupus, 2019 Oct;28(11):1337-1343. (Also see Treatments for Lupus and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double–Blind, Placebo–Controlled, Pilot Trial. Significant decrease in expression of B–cell signaling and pro–fibrotic genes and pathways was observed in patients with improved modified Rodnan skin score in the belimumab group but not in the placebo group. PubMed, Arthritis Rheumatol, 10/26/2017. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.